findmyKOL
Clinical trialNCT03775850CompletedPhase 1Interventional

A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

SponsorEvelo Biosciences, Inc.Enrollment69Bladder CancerColorectal Cancer MetastaticGastroEsophageal CancerMSI-HNon Small Cell Lung CancerRenal Cell Carcinoma+1 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is being conducted to assess the safety, tolerability, and efficacy of EDP1503 alone and in combination with pembrolizumab in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, and checkpoint inhibitor relapsed tumors
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada
  • Centre de Recherche Du Chum

    Montreal, Quebec, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • Chu de Québec - Université Laval

    Québec, Canada

United States
  • Highlands Oncology Group

    Rogers, Arkansas, United States

  • Florida Cancer Specialists

    Sarasota, Florida, United States

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma, United States

  • Tennessee Oncology, Pllc

    Chattanooga, Tennessee, United States

  • Tennessee Oncology

    Nashville, Tennessee, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

EDP1503Pembrolizumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
19 Dec 2018
Primary completion
30 Jun 2021
Completion
31 Oct 2021
Last update posted
24 Mar 2023
Registered enrollment
69
Registry id
NCT03775850
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.